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Abstract
Background—With the advent of the direct-acting antiviral agents (DAAs), significant drug-
drug interaction (DDI) potential now exists for patients treated for chronic hepatitis C virus (HCV)
infection. However, little is known about how often patients with HCV use medications that may
interact with newer HCV treatments, especially those with CYP3A DDI potential.
Methods—Using a large United States commercial insurance database, medication use and
comorbidity burden was examined among adult patients with a chronic HCV diagnosis from
2006-2010. Medications were examined by total number of prescription claims, proportion of
patients exposed, and DDI potential with prototypical CYP3A DAAs, boceprevir and telaprevir,
for which data were available.
Results—Patient comorbidity burden was high and increased over the study period. Medication
use was investigated in 53,461 patients with chronic HCV. Twenty-one (53%) of the top 40 most
utilized medications were classified as having interaction potential, with 62% of patients received
at least one of the top 22 interacting medications by exposure. Of these, 59% and 41% were listed
in a common DDI resource but not in medication prescribing information, 77% and 77% had not
been investigated in DDI studies, 32% and 27% did not have clear recommendations for DDI
management, and only 14% and 23% carried a recommendation to avoid coadministration for
boceprevir and telaprevir, respectively.
Conclusion—Practitioners may expect a medication with CYP3A DDI potential in two-thirds of
patients with HCV and almost one-half of the most frequently used medications. However, DDI
potential may not be reflected in prescribing information.
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Chronic hepatitis C virus infection (HCV) affects an estimated 3.2 million people in the
United States (U.S.), while in the European Union HCV affects approximately 8.1 million
people and contributes to one-third of deaths in patients with cirrhosis or liver cancer [1-3].
The introduction of direct-acting antivirals (DAAs), beginning with telaprevir (TVR) and
boceprevir (BOC) in 2011, has revolutionized the treatment of genotype 1 chronic HCV by
improving rates of sustained virologic response dramatically in conjunction with
peginterferon and ribavirin (triple therapy) [4]. Currently, there are three classes of DAAs
that target different steps in the viral replication cycle: NS3/4A protease inhibitors, NS5B
polymerase inhibitors, and NS5A inhibitors. Despite advantages in improving virologic
response, many of these new DAAs also carry high drug-drug interaction (DDI) potential
due to their metabolism by cytochrome P450 3A (CYP3A) or transport by P-glycoprotein
(P-gp) [5].
A number of DDI studies for DAAs have been conducted in both healthy volunteers and
diseased populations [6-9] with a focus on medications that have the potential for significant
drug interaction or which may be highly utilized in certain patient populations [6, 10, 11].
Recent review articles have provided some guidance for the clinical management of DDIs
with the use of NS3/4A protease inhibitors TVR and BOC based on a composite of available
literature and theoretical considerations of their clinical pharmacology [5, 12-15]. However,
there is a paucity of information on their actual DDI risk in the outpatient setting. Recently,
DDI risk with initiation of NS3/4A protease inhibitor therapy was determined to be
substantial for about one-half of a small cohort of German HCV patients at a tertiary referral
center [16]. Knowledge of the medication use patterns in a larger heterogeneous population
would add vital insight to our understanding of the potential for interactions with current and
emerging agents [5, 13].
The primary objective of this study was to characterize medication utilization in a
representative chronic HCV population. Specific aims included: (1) to assess the most
highly utilized medications from 2006-2010 by prescription claims and by exposure, and (2)
to evaluate the telaprevir and boceprevir DDI potential of highly utilized medications in
patients with HCV. In order to provide a context for interpretation of the medication use
data, comorbidities and other demographic and clinical characteristics of the patients with
chronic HCV also were explored. The DDI risk for boceprevir and telaprevir, prototypical
CYP3A-metabolized DAAs, will be similar to the DDI risk for other DAAs which are
substrates or inhibitors of CYP3A such as simeprevir, faldaprevir, or daclatasvir and
especially for DAAs that will be co-administered with ritonavir to inhibit their CYP3A-
dependent metabolism (ABT-450 and danoprevir). These agents will soon be used
extensively in patients with HCV throughout the world.
Materials and Methods
Study Population and Data
A retrospective observational study design was employed using the Truven Health Analytics
Marketscan® Commercial Claims and Encounters Research Database for the years 2006 to
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2010. The database includes de-identified medical inpatient and outpatient claims, outpatient
pharmaceutical claims, and enrollment data files and provides demographic information,
medical diagnoses, health care procedures, and pharmacy claims for approximately 20
million enrollees from over 100 nationwide U.S. insurers.
Five different 1-year cross-sectional cohorts were constructed for each year from 2006 to
2010 to examine demographic characteristics, medication use, and comorbid health
conditions in chronic HCV patients. Within each 1-year cross-section, patients were selected
for inclusion if they 1) had at least 1 inpatient or 2 outpatient International Classification of
Diseases, 9th edition (ICD-9) codes for chronic HCV (070.54 or 070.44) occurring on
separate days, 2) were ≥18 years of age, 3) and had continuous enrollment for the entire 1-
year period. This cohort was used to investigate demographic and clinical characteristics. A
subcohort of these patients with prescription insurance benefits filling at least one
prescription per year was further selected to examine concomitant medication use. This
subcohort was identified to ensure adequate capture of prescription claims information.
Given the prevalent cross-sectional nature of this study, patients could contribute to multiple
cross-sections if meeting eligibility criteria for multiple years.
Demographic and Clinical Characteristics
To characterize patients with HCV eligible to receive telaprevir or boceprevir, information
was captured for each 1-year calendar period including demographic (age and gender), type
of insurance coverage, and region of residence (e.g., Northeast, North Central, South or
West). In addition, comorbidities that were reported previously as highly prevalent in
chronic HCV patients or otherwise believed to be clinically relevant were identified for each
1-year cross-sectional cohort in either the inpatient or outpatient files using compiled ICD-9
code definitions from the medical literature (Appendix A) [17, 18]. Compensated cirrhosis
was defined directly by ICD-9 code definition; advanced liver disease was a composite
definition representing decompensated disease and included codes for ascites, spontaneous
bacterial peritonitis, hepatic encephalopathy, portal hypertension, esophageal varices,
hepatorenal syndrome, or hepatocellular carcinoma. The Charlson Comorbidity Index (CCI),
a general measure of comorbidity and predicted mortality, was calculated for each 1-year
cross-sectional cohort [19, 20].
Medication Use
Medication use was characterized among the subcohort of chronic HCV patients with
prescription insurance benefits. Prescription drug use was identified through national drug
codes (NDCs) in the outpatient pharmaceutical files merged with the REDBOOK
supplement, which identifies specific medications and therapeutic categories. As standard of
care during the study period was dual therapy with interferon and ribavirin, a ‘treated’
patient was defined as having ≥ 1 prescription claim for ribavirin plus ≥1 prescription claim
for peginterferon alfa-2a/2b or interferon alfacon-1 during each 1-year eligible calendar
period. The average number of distinct medications per individual (drug name without
regard to strength or form) also was calculated within the 1-year calendar period for eligible
enrollees.
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To identify highly utilized medications in the chronic HCV cohort, the 200 most commonly
used medications were identified and ranked according to the total number of prescription
claims. These medications were then assessed for the potential to interact with telaprevir or
boceprevir using the University of Liverpool Hepatitis DDI website (as of September 2013),
a recommended international resource from the American Association for the Study of Liver
Diseases (AASLD) HCV treatment guidelines [21]. This resource was used as prior data,
because it has been suggested to be a more comprehensive resource than the prescribing
information [22, 23]. Drug interactions with telaprevir and boceprevir are designated on this
site as: “should not be coadministered”, “potential interaction”, or “no clinically significant
interaction expected” [21].
To identify the annual proportion of HCV patients exposed to medications with known
telaprevir and boceprevir DDI potential, medications were selected from the Liverpool
resource's printable charts (as of April 2013) if classified as either “should not be
coadministered” or “potential interaction” [21]. For each of these medications, the
proportion of patients with ≥1 outpatient prescription claim during each 1-year period of
eligibility was determined. Medications were then ranked by average annual proportion of
patients exposed within each 1-year cross-sectional cohort. Medications were queried by
individual drug ingredients such that one query could span multiple products, identifying
usage by total exposure rather than through individually marketed products. For example,
codeine was not ranked on the top 40 medications by claims when comparing individual
drug products, but its total population exposure was 8.9% across multiple drug products.
Medications with drug interaction potential in the Liverpool resources' complete
recommendations were selected for subanalysis if they were listed in the top 40 most
utilized medications by prescription claims or had high patient exposure. The prescribing
information was compared with the Liverpool resource charts for the selected medications.
Drug interaction details in the Liverpool resource were used to further analyze the
proportion of these drugs with DDI potential formally investigated in studies, the proportion
with clear and actionable recommendations for DDI management, and the proportion not
recommended for coadministration. A recommendation for DDI management was
considered clear and actionable if there was a statement advising an action such as avoiding,
adjusting dose, monitoring, or therapeutic drug monitoring.
Statistical Analysis
For each 1-year cross-sectional cohort, descriptive statistics were performed to assess each
demographic and clinical characteristic, including the proportion of patients ‘treated’ with
PEG-interferon and ribavirin and comorbid conditions. An average from 2006-2010 across
each characteristic was weighted by the total number of patients in each year. In addition,
the annual proportions of patients utilizing medications present in the top 200 drug list and
those defined by our team as clinically relevant in the chronic HCV population were also
described.
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All analyses were performed using SAS 9.2 (SAS institute, Cary, NC). This study was
approved by the University of North Carolina at Chapel Hill Institutional Review Board.
Results
Of 197,381 individuals aged ≥18 with any HCV diagnosis in the study period, 71,584
patients (106,283 1-year cross-sections) received a diagnosis of chronic HCV in at least one
inpatient or two outpatient visits and maintained continuous enrollment for at least one 1-
year period. Demographic and clinical comorbidity characteristics are reported in Table 1.
There were fewer eligible individuals in 2006 and 2007 relative to the successive years.
Average overall age of the study sample was 51.2 ± 7.5 years with an increasing trend over
the 5-year period from age 49.7 in 2006 to age 52.4 in 2010; 62.2% were male. The majority
of the study patients resided in the Southern region of the U.S. (48.6%) and had a preferred
provider organization insurance plan (65.7%). Comorbid conditions prevalent in ≥5% of
patients (in order of decreasing prevalence) were hypertension, lipid metabolism disorders,
compensated cirrhosis, advanced liver disease, type 2 diabetes, depression, non-alcoholic
fatty liver disease (NAFLD), and chronic obstructive pulmonary disease (COPD)/asthma.
Prevalence increased over the study period for the majority of conditions queried, with the
highest increases observed for obesity, hepatocellular carcinoma, and alcohol abuse/
dependence. Average rates of liver transplant and human immunodeficiency virus/acquired
immunodeficiency syndrome (HIV/AIDS) in the cohort were 3.9% and 2.8%, respectively.
A subcohort of 53,461 individuals (79,185 cross-sections) had prescription insurance
benefits and was followed to examine medication use patterns. HCV treatment rates and
comorbidity measures for this subcohort are reported in Table 2. On average, 31.2% of
patients were classified as ‘treated’, having received both interferon and ribavirin. The mean
Charlson Comorbidity Index score was 2.2 and increased over the study period; the average
for the treated group was lower than the untreated group (1.9 vs 2.4, respectively). The
average number of unique medications filled per patient for the treated group was higher
than the untreated group (11.5 vs 8.9, respectively).
The top 10 therapeutic medication categories used in this chronic HCV cohort included (1)
analgesics/antipyretics and opiate agonists, (2) antidepressants, (3) antivirals, (4)
gastrointestinal drugs, (5) benzodiazepines, (6) beta-blockers, (7) ACE-inhibitors, (8)
anxiolytic/sedative hypnotics, (9) calcium channel blockers, and (10) interferons. The top 40
medications used by HCV patients from 2006-2010 are displayed in Table 3, with the top
200 listed in Appendix B. The most common medication with DDI potential used by HCV
patients was acetaminophen/hydrocodone, which was filled 367,166 times among the 53,461
patients with HCV who had prescription insurance benefits between 2006 and 2010.
Examination of the top 40 medications for DDI potential with boceprevir or telaprevir in the
Liverpool resource showed that 17 were classified as “no clinically significant interaction
expected” (42.5%), 21 contained at least one component that was classified as “potential
interaction” (52.5%, 5 of which indicated an unlikely pharmacokinetic interaction and/or a
drug-disease interaction only), zero medications were classified as “should not be
coadministered” (0%), and 2 medications (5.0%) were not listed in the resource.
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Of 225 drugs listed in the Liverpool resource, 143 were categorized as “potential
interaction” or “should not be coadministered” with boceprevir or telaprevir. Of these, 109
were selected for analysis if they had FDA approval during the study period and were not
classified as a drug-disease interaction. The medication with the highest exposure was
zolpidem, which was used by 14.1% of the subcohort. Medications demonstrating increasing
utilization over the study period included pravastatin, tenofovir, buprenorphine, simvastatin,
amlodipine, tacrolimus, and prednisone; decreasing utilization was observed for
escitalopram and venlafaxine. Simvastatin, which is contraindicated with telaprevir and
boceprevir, showed a notable increase in utilization between 2006 and 2010.
Of the most utilized medications by prescription claims or exposure, a subset of 22 highly
utilized medications was examined further. The Liverpool resource recommendations are
summarized in Table 4. For telaprevir, 13 (59.1%) were listed in the prescribing
information, 16 (72.7%) carried a clear recommendation for DDI management, 5 (22.7%)
carried a recommendation to avoid coadministration, and 5 (22.7%) were investigated
formally in a DDI study. For boceprevir, 9 (40.9%) were listed in the prescribing
information, 15 (68.2%) carried a clear recommendation for DDI management, 3 (13.6%)
carried a recommendation to avoid coadministration, and 5 (22.7%) were investigated
formally in a DDI study. These 22 medications with drug interaction potential are listed by
exposure in Table 5. On average, 62.1% of chronic HCV patients were exposed to any of
these 22 medications.
A complete listing of percentages using specific queried medications can be found in
Appendix C, including rates of utilization for the medications with DDI potential.
Discussion
Medication utilization has been historically inferred from clinical knowledge or extracted
from limited clinical trial data. To our knowledge, this is the first published systematic
investigation of modern day clinical medication utilization in a large, real-world database of
patients with chronic HCV. Previous studies have been smaller or examined potential
interactions within a strictly controlled setting. A 2011 analysis examined the use of certain
co-medications with boceprevir triple therapy in three major late phase studies; however,
patients with certain comorbidities were excluded, limiting the study's generalizability. [10,
24-26]. Recently, Maasoumy et al. investigated DDI risk during initiation of HCV protease
inhibitor therapy in 115 consecutively treated patients seen at a German tertiary referral
center. They reported that 38% of 116 outpatient medications used in their cohort had DDI
potential or unknown DDI risk and that 49% of patients were exposed to at least one drug
with DDI potential during treatment [16]. The four most frequently encountered medication
classes in the German cohort included beta-blockers, proton pump inhibitors (PPIs), thyroid
hormones, and dihydropyridine calcium channel blockers (CCBs) (e.g., amlodipine), and
only 4% of encountered drugs were strictly contraindicated [16]. In contrast, in our large
U.S. cohort of chronic HCV subjects (not restricted by treatment), the four most frequently
used drug categories included analgesics/antipyretics and opiate agonists, antidepressants,
antivirals, and gastrointestinal drugs including PPIs. In our study, 57.5% of the top 40
outpatient medications had DDI potential or unknown DDI risk, and 62% of patients were
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exposed to at least one of the twenty-two most highly utilized medications with DDI
potential. Medications with DDI potential used by greater than 9% of patients included
zolpidem, alprazolam, amlodipine, and prednisone. Based on both studies, the DDI risk
appears to be substantial among chronic HCV patients.
Our study also demonstrates increasingly high comorbidity burden in patients with chronic
HCV, based on rates of specific comorbidities as well as Charlson Comorbidity Index. A
small cross-sectional retrospective study investigating comorbidities associated with HCV
from 1998 to 2007 found that HIV/AIDS, renal disease, diabetes, and obesity were more
prevalent in patients with HCV compared with the U.S. population [27]. Higher comorbidity
rates may reflect the selective age distribution of the HCV population, but there is also some
recent evidence that comorbidity rates may be higher in the HCV population even after
adjusting for age [17]. In our study, the potential increasing comorbidity rates may be
related to the increasing average age of the underlying HCV population and have
implications for increasing polypharmacy and complexity of DDI assessment.
As a result, it is important that practitioners be familiar with current DDI management
recommendations. However, as observed with approximately one-third of the drugs
identified in this study, many potential DDIs have not been studied formally and thus clear
and actionable DDI recommendations often are absent. For those DDIs that do provide
actionable recommendations, DDI management depends upon the nature of the interaction.
The most well characterized DDIs with telaprevir and boceprevir are those involving the
inhibition or induction of oxidative metabolism by CYP3A. For simvastatin (the most highly
utilized statin in this population, Appendix B), reasonable intervention options exist and
include employing a “statin holiday” by removing medication for the duration of treatment,
or stabilizing a patient on an alternative statin with lower interaction potential prior to
therapy [28]. For other drugs such as salmeterol, fluticasone, or other inhaled
corticosteroids, alternatives such as formoterol or beclomethasone may be employed [5].
Comparatively, use of systemic corticosteroids may be unavoidable in some settings such as
maintenance immunosuppression in the transplant setting, and providers must weigh the risk
of reduced efficacy of telaprevir and boceprevir due to the possible induction of CYP3A [5,
29, 30]. Management of depression-like symptoms during treatment with peginterferon-
based therapies has been shown to affect treatment outcomes and often involves the use of
antidepressants such as selective serotonin reuptake inhibitors (SSRIs). [31] SSRIs are
generally metabolized by multiple CYP450 enzymes with CYP3A providing only partial
contribution, and therefore, the risk of a clinically significant CYP3A-mediated DDI with
DAAs is low [5, 14]. In addition, a recent review of data from major clinical trials by
Sockalingam et al investigating the neuropsychiatric adverse effects of DAAs as well as
DDIs between DAAs and psychiatric medications concluded that DAAs have minimal
neuropsychiatric risk [32]. Opioids and other analgesics also are metabolized by multiple
pathways including CYP3A, but they are often self-titrated by patients for pain control,
complicating the risk of DDIs [33, 34]. In addition, they often are used in combination with
acetaminophen, which may represent the greatest risk to patients because providers may not
recognize the daily acetaminophen dose from all sources [35].
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Less characterized DDIs with boceprevir and telaprevir are those involving hepatic transport
proteins [36]. Boceprevir appears to be an inhibitor of organic anion transporting
polypeptide 1B (OATP1B) while telaprevir is an inhibitor of OATP1B1 and OATP1B3,
organic cation transporter 1 (OCT1), and multidrug and toxin extrusion 1 (MATE1); these
transporters are involved in the active uptake of drugs in the liver [36, 37]. Inhibition of
these transporters may result in higher systemic exposures but reduced hepatic exposure and
efficacy of drugs targeting the liver (e.g., statins, metformin, valsartan) [38-40]. Boceprevir
also appears to be a substrate of breast cancer resistance protein (BCRP), a hepatic
transporter involved in the active biliary elimination of drugs from the liver [37]. Drugs that
are substrates/inhibitors of BCRP (e.g., eltrombopag, cyclosporine) may potentially inhibit
the biliary elimination of boceprevir resulting in higher hepatic exposure [41, 42].
Alternatively, boceprevir could increase the hepatotoxic potential of other co-administered
BCRP substrates (e.g., methotrexate, rosuvastatin, lapatinib) [43-45]. Additional
examination of the potential interactions involving elimination pathways mediated by
hepatic transport proteins is needed.
While many drug interactions are predicted from a theoretical understanding of the drug's
clinical pharmacology, most are never investigated in DDI studies. Accordingly, at the time
of this study, many drugs with theoretical DDI potential through CYP3A had not been
formally investigated. While it is impractical and cost-prohibitive to study every possible
drug interaction in a formal DDI study, it is also imprudent to risk treatment failure or
toxicity without a sound understanding of the DDI potential in a real-world setting.
Theoretical prediction is limited by our scientific understanding, which is particularly
evident with transporter interactions where the science is in its infancy. In order to mitigate
risk, computer simulation with tools such as SimCyp should be considered prior to drug
approval to complement formal in vivo studies and establish a better framework for reliable
DDI prediction [46, 47]. However, much of the DDI knowledge will still be derived from
post-marketing studies and expert opinion, as demonstrated by the majority of interacting
medications in this study that were listed in the Liverpool resource but not in the prescribing
information. Here, methods such as DDI registries and pharmacovigilance algorithms may
complement in vivo studies for detection of DDIs quickly and efficiently [21, 48]. As DDI
information is discovered, the prescribing information will remain a reliable source of
information about formal DDI studies that were performed by the pharmaceutical company,
but resources that are comprehensive, regularly updated, and maintained by clinical experts,
such as the Liverpool database, may provide a more optimal model for access to actionable
DDI information [21]. The sensitivity and specificity of disease-specific resources such as
the Liverpool database also should be compared with other widely-used, validated
interaction checking software such as ePocrates [49].
This study has several limitations. ICD-9 definitions, though applied from validated studies,
may differ from other definitions such as the Clinical Classification Software from the U.S.
Agency for Healthcare Research and Quality; this may partially account for slight
differences in comorbidity rates observed in other reports [17, 27]. Medication use was
explored in the chronic HCV cohort and not limited to treated patients, so conclusions
should be drawn in this context. In addition, only outpatient medication claims were
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evaluated, so utilization rates may not appropriately estimate medications with use limited to
hospital settings. Over-the-counter medications could not be evaluated in this database. This
study also was restricted to insured HCV subjects in the U.S. and may not be fully
representative of the typical U.S. HCV population [50] or populations in other parts of the
world where treatment patterns and comorbidities may differ. However, this study is
significant because it examined a wide range of potential prescription medications available
both in the U.S. and worldwide for their interaction potential with boceprevir and telepravir,
and this information was integrated with the actual exposure to these medications in a real-
world setting.
While the focus of this study was to inform DDI assessment for currently available agents,
these findings also may have strong implications for other candidates in development. Two
new DAAs, simeprevir and sofosbuvir, have been recently approved and others are in Phase
3 evaluation for HCV treatment [51, 52]. An all-oral regimen utilizing a protease inhibitor
boosted with ritonavir (ABT-450/r), combined with an NS5A inhibitor and a non-nucleoside
polymerase, will likely be licensed by the end of 2014. Moreover, faldaprevir and
daclatasvir, which are currently undergoing approval in both the U.S. and Europe, have been
shown to be CYP3A substrates and require dose-reductions when used in combination with
a ritonavir-boosted anti-retroviral [3, 53-55]. Thus, the information learned here from
examining the first two prototypical CYP3A DAAs will remain highly relevant and
applicable [56]. As knowledge increases regarding the mechanism(s) and role(s) of
metabolism and transport for various drugs, particularly in the setting of liver disease, the
information provided here will become highly relevant.
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Appendix A. ICD-9 Code Definitions for Selected Comorbidities
Disease State ICD-9 Codes
Advanced liver disease (includes any of the following: ascites,
spontaneous bacterial peritonitis, hepatic encephalopathy, portal
hypertension, esophageal varices, hepatorenal syndrome,
hepatocellular carcinoma)
070.44, 070.71, 456.0, 456.1, 456.2x, 572.2,
572.3, 572.4, 572.8, 789.59, 567.23, 155.x
Alcohol abuse or dependence 303.xx, 305.0x, 291.xx
Alcoholic liver disease (includes alcoholic fatty liver, acute
alcoholic hepatitis, alcoholic cirrhosis of liver, alcoholic liver
damage unspecified)
571.0-, 571.1-, 571.2-, 571.3-
Bipolar disorders 296.0x, 296.1x, 296.4x-296.7x, 296.80, 296.89
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Disease State ICD-9 Codes
Compensated cirrhosis (alcoholic, nonalcoholic, biliary) 571.2-, 571.5-, 571.6-
COPD/asthma 491.xx-493.xx, 496.x
Depression 296.2x, 296.3x, 311, 309.1, 300.4
Diabetes 250.xx
Drug abuse or dependence (non-tobacco) 292.xx, 304.xx, 305.2x-305.9x
Hepatocellular carcinoma (malignant neoplasm of liver and
intrahepatic bile ducts)
155.x
HIV/AIDS, asymptomatic HIV infection, HIV-2 042.xx, V08, 079.53
Hypertension 401.xx, 402.xx, 403.xx, 404.xx, 405.xx
Lipid metabolism disorders 272.xx
Liver transplant V42.7, 50.5x; 996.82, CPT codes 47135, 47136
Non-alcoholic fatty liver disease 571.8
Overweight and obesity 278.0x
Rheumatologic disease 710.xx, 714.xx, 725.xx
Viral hepatitis B with or without hepatic coma, or carrier 070.2x, 070.3x, V02.61
Abbreviations: ICD-9, International classification of disease, 9th edition; HIV, human immunodeficiency virus; AIDS,
acquired immunodeficiency syndrome; CPT: Current Procedural Terminology
Appendix B. Drug Interaction Potential of Top 200 Drugs in Chronic HCV
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34. Cyclobenzaprine HCl NL NL
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40. Carisoprodol NL NL
41. Fluoxetine HCl
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54. Estradiol NL NL
55. Simvastatin
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59. Amlodipine Besylate/Benazepril HCl
60. Nadolol NL NL
61. Levofloxacin
62. Duloxetine HCl
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67. Glipizide NL NL
68. Fexofenadine HCl
69. Tamsulosin HCl
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76. Fluticasone Propionate/Salmeterol Xinafoate
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77. Clopidogrel Hydrogen Sulfate
78. Triamcinolone Acetonide NL NL
79. Amitriptyline HCl
80. Hydrocodone Bitartrate/Ibuprofen
81. Valacyclovir HCl NL NL
82. Hydrochlorothiazide/Valsartan
83. Warfarin Sodium
84. Eszopiclone NL NL
85. Methylprednisolone
86. UrsodiolA
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97. Acyclovir NL NL
98. Naproxen
99. Doxycycline Hyclate
100. Meloxicam NL NL
101. Alendronate SodiumA 101
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116. Rabeprazole Sodium NL NL
117. Rifaximin
118. Verapamil HCl
119. Amphetamine Salt Combination
120. Clindamycin HCl
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122. Ergocalciferol NL NL





128. Clobetasol Propionate NL NL
129. Olmesartan Medoxomil
130. Insulin Aspart, Recombinant NL NL
131. Benazepril HCl NL NL
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139. Tizanidine HCl NL NL
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141. Sumatriptan Succinate NL NL
142. Varenicline
143. Hydrochlorothiazide/Losartan Potassium
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150. Modafinil NL NL
151. Penicillin V Potassium
152. Tiotropium Bromide NL NL
153. Testosterone NL NL
154. Codeine Phosphate/Promethazine HCl
155. Ritonavir
156. Methocarbamol NL NL
157. Sitagliptin Phosphate
158. Ondansetron HCl
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159. Nystatin NL NL
160. Hydroxychloroquine Sulfate
161. Acetaminophen/Butalbital/CaffeineA
162. Benzonatate NL NL
163. Methylphenidate HCl
164. Albuterol Sulfate/Ipratropium BromideA





NL / NL NL / NL
169. Quinapril HCl
170. Cetirizine HCl NL NL
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172. Ropinirole HCl NL NL
173. Insulin Human Isophane (NPH) NL NL
174. Lithium Carbonate
175. Metaxalone NL NL
176. Clarithromycin
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182. Betamethasone Dipropionate/ Clotrimazole NL / NL NL / NL





188. Mupirocin NL NL
189. Colchicine
190. Niacin NL NL
191. Hydrochlorothiazide/Irbesartan
192. Famotidine NL NL
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193. Atropine Sulfate/Diphenoxylate HCl NL / NL NL / NL
194. Fluocinonide NL NL




199. Chlorhexidine Gluconate NL NL
200. PEG Electrolyte Lavage Solution NL NL
Abbreviations: HCV, Hepatitis C Virus; NL, Not listed;
A
Names differ between MarketScan database and hep-druginteractions.org as follows, respectively: acetaminophen listed
as paracetamol, propoxyphene listed as dextropropoxyphene, albuterol listed as salbutamol, cephalexin listed as cefalexin,
ursodiol listed as ursodeoxycholic acid, alendronate listed as alendronic acid, Omega-3-Acid Ethyl Esters listed as fish oils,
cyclosporine listed as ciclosporin
B
Drugs list different recommendation for different indication/usage
*Hep-druginteractions.org last accessed 9/11/2013
 No clinically significant interaction expected
 Potential interaction – may require close monitoring, alteration of drug dosage or timing of administration
 These drugs should not be coadministered
Empty symbols indicate the interaction has not been assessed and has been predicted based on the metabolic profiles of the
drugs.
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Appendix C. Comprehensive List of Queried Drugs with Population
Exposures from 2006-2010, by Medication Class
2006 2007 2008 2009 2010 Weighted Average
(53,461 beneficiaries, 79,185 cross-sections)




ribavirin 27.6 24.3 21.1 20.1 16.9 21.3
peginterferon alfa-2a 16.2 14.2 13.3 14.0 12.5 13.8
peginterferon alfa-2b 10.5 9.3 6.9 5.2 4.0 6.7
interferon alfacon-1 2.2 1.8 1.2 1.1 0.9 1.3
Side Effect Management
epoetin alfa 5.6 4.5 3.5 3.0 2.5 3.6
filgrastim 2.8 2.6 2.2 2.1 1.7 2.2
darbepoetin alfa 0.4 0.3 0.2 0.2 0.2 0.2
Transplant
tacrolimus 2.5 2.7 2.9 3.3 3.5 3.0
mycophenolate 1.6 1.7 1.9 2.2 2.3 2.0
cyclosporine 1.2 1.1 1.1 1.2 1.4 1.2
sirolimus 0.5 0.4 0.4 0.5 0.5 0.5
azathioprine 0.6 0.5 0.5 0.6 0.5 0.5
NERVOUS SYSTEM
Antidepressants
escitalopram 7.9 7.4 6.2 6.0 5.1 6.4
bupropion 6.8 6.0 5.2 5.7 5.4 5.7
citalopram 4.2 4.7 4.8 6.1 6.4 5.4
trazodone 5.2 5.0 4.8 5.5 6.0 5.3
sertraline 5.3 5.2 4.9 5.1 4.9 5.1
fluoxetine 3.7 3.5 3.4 3.7 3.4 3.5
venlafaxine 4.5 4.3 3.4 3.1 2.4 3.4
paroxetine 3.7 3.3 2.9 2.8 2.4 3.0
duloxetine 2.6 3.0 2.8 2.8 2.5 2.7
amitriptyline 2.7 2.7 2.3 2.5 2.3 2.5
mirtazapine 1.4 1.5 1.3 1.4 1.5 1.4
nortriptyline 0.8 0.8 0.8 1.0 1.0 0.9
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2006 2007 2008 2009 2010 Weighted Average
doxepin 0.7 0.7 0.6 0.8 0.7 0.7
desipramine 0.1 0.1 0.1 0.1 0.1 0.1
Antipsychotics / Neuroleptics
quetiapine 1.9 2.2 2.1 2.2 2.2 2.1
prochlorperazine 1.8 1.9 1.9 1.7 1.8 1.8
aripiprazole 0.6 0.5 0.7 1.1 1.1 0.8
lithium carbonate 0.6 0.6 0.5 0.6 0.7 0.6
risperidone 0.6 0.6 0.6 0.6 0.7 0.6
olanzapine 0.9 0.6 0.5 0.6 0.5 0.6
clozapine 0.0 0.0 0.0 0.0 0.0 0.0
pimozide 0.0 0.0 0.0 0.0 0.0 0.0
Anxiolytics / Sedatives / Hypnotics
zolpidem 15.0 14.4 13.6 14.1 14.0 14.1
alprazolam 9.7 10.6 9.2 10.0 9.9 9.8
lorazepam 5.5 5.4 5.4 5.9 6.1 5.7
diazepam 4.9 5.0 5.0 5.4 5.1 5.1
temazepam 3.2 3.6 2.9 3.2 3.1 3.2
eszopiclone 3.8 3.5 2.4 1.9 1.9 2.5
buspirone 1.0 1.0 0.9 1.0 1.0 1.0
triazolam 0.4 0.5 0.4 0.5 0.4 0.5
midazolam (iv) 0.0 0.0 0.0 0.0 0.0 0.0
midazolam (po) 0.0 0.0 0.0 0.0 0.0 0.0
Opioid Dependence
methadone 1.4 1.2 1.2 1.3 1.4 1.3
buprenorphine 0.6 0.7 1.0 1.3 1.5 1.1
Pain
hydrocodone 33.7 35.0 32.0 35.5 34.9 34.2
oxycodone 14.6 14.9 15.1 16.5 17.7 15.9
tramadol 7.8 8.7 8.2 9.7 10.0 9.0
codeine 8.0 7.9 9.0 9.6 9.1 8.9
gabapentin 4.3 4.8 4.9 5.7 6.6 5.4
morphine sulfate 1.8 2.2 2.1 2.6 2.6 2.3
hydromorphone 1.5 1.8 2.1 2.6 2.5 2.2
fentanyl 1.8 1.8 1.8 1.7 1.6 1.7
meperidine 1.5 1.1 1.0 0.7 0.7 0.9
oxymorphone 0.0 0.3 0.4 0.4 0.4 0.3
Muscle Relaxants
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2006 2007 2008 2009 2010 Weighted Average
cyclobenzaprine 7.8 7.6 7.5 8.6 8.5 8.1
carisoprodol 3.2 3.5 3.0 3.2 3.0 3.2
methocarbamol 1.5 1.8 1.6 1.7 2.1 1.8
metaxalone 2.1 2.2 1.7 1.3 1.1 1.6
tizanidine 1.3 1.4 1.2 1.2 1.3 1.3
Migraine
sumatriptan 1.3 1.2 1.2 1.2 1.5 1.3
ergotamine 0.2 0.1 0.0 0.1 0.0 0.1
dihydroergotamine 0.1 0.0 0.0 0.0 0.0 0.0
methylergonovine 0.0 0.0 0.0 0.0 0.0 0.0
Anticonvulsants
clonazepam 3.9 4.1 3.9 4.3 4.4 4.1
lamotrigine 1.0 1.0 1.1 1.2 1.4 1.2
topiramate 1.2 1.2 1.0 1.1 1.2 1.1
levetiracetam 0.3 0.4 0.5 0.7 0.7 0.5
phenytoin 0.4 0.4 0.4 0.4 0.4 0.4
carbamazepine 0.3 0.4 0.3 0.3 0.3 0.3
phenobarbital 0.1 0.1 0.1 0.2 0.2 0.1
Miscellaneous
pregabalin 2.0 2.8 2.8 2.6 2.1 2.5
varenicline 0.8 4.1 2.9 2.5 1.9 2.4
modafinil 1.2 1.2 1.1 1.0 0.8 1.0
amphetamine salt 0.9 0.8 0.8 0.9 1.0 0.9
methylphenidate 0.8 0.8 0.6 0.7 0.9 0.7
ropinirole 0.7 0.8 0.5 0.7 0.8 0.7
METABOLIC
Hypertension / Cardiovascular
hydrochlorothiazide 14.4 15.6 15.0 16.0 16.3 15.5
lisinopril 8.6 10.9 11.4 13.1 14.5 12.0
furosemide 8.1 9.1 8.9 9.8 10.8 9.5
spironolactone 6.5 6.4 6.3 7.2 8.1 7.0
valsartan 3.4 3.4 3.8 3.7 4.0 3.7
benazepril 3.1 3.3 2.9 3.0 2.7 3.0
lidocaine (IV) 2.2 2.3 2.5 2.6 2.4 2.4
triamterene 2.8 2.6 2.3 2.4 2.2 2.4
clonidine 2.1 2.3 2.0 2.1 2.3 2.1
olmesartan 1.7 2.2 2.1 2.4 2.1 2.1
losartan 1.9 2.0 1.7 2.1 2.7 2.1
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2006 2007 2008 2009 2010 Weighted Average
clopidogrel 1.7 2.0 1.9 2.1 1.9 1.9
ramipril 1.7 1.4 1.2 1.1 1.0 1.2
enalapril 1.2 1.0 1.2 1.1 1.0 1.1
irbesartan 1.3 1.0 1.3 1.1 0.8 1.1
digoxin (oral) 0.5 0.6 0.6 0.5 0.5 0.5
amiodarone 0.1 0.2 0.2 0.2 0.3 0.2
flecainide 0.1 0.0 0.1 0.1 0.1 0.1
propafenone 0.0 0.1 0.1 0.1 0.1 0.1
sildenafil (Revatio) 0.1 0.1 0.1 0.1 0.2 0.1
bosentan 0.0 0.0 0.0 0.0 0.0 0.0
quinidine 0.0 0.0 0.0 0.0 0.0 0.0
tadalafil (Adcirca) 0.0 0.0 0.0 0.0 0.0 0.0
Beta Blockers
metoprolol 7.1 8.0 7.7 8.0 8.1 7.8
atenolol 4.4 4.6 4.4 4.5 4.0 4.4
propranolol 3.1 3.5 3.3 3.7 3.8 3.5
nadolol 2.3 2.3 2.6 3.0 3.4 2.8
carvedilol 1.0 1.5 1.8 2.2 2.3 1.8
bisoprolol 0.5 0.5 0.4 0.4 0.4 0.5
nebivolol N/A N/A 0.2 0.6 0.8 0.5
Calcium Channel Blockers
amlodipine 7.5 7.7 8.8 10.3 10.9 9.3
diltiazem 1.8 1.5 1.3 1.4 1.6 1.5
nifedipine 1.2 1.3 1.4 1.4 1.4 1.4
verapamil 1.5 1.3 1.1 1.1 1.0 1.2
felodipine 0.5 0.5 0.4 0.3 0.3 0.4
nisoldipine 0.2 0.3 0.2 0.1 0.1 0.2
nicardipine 0.0 0.0 0.0 0.0 0.0 0.0
Hyperlipidemia
nicardipine 0.0 0.0 0.0 0.0 0.0 0.0
Hyperlipidemia
any statin queried 5.9 7.3 7.4 9.3 9.1 8.0
simvastatin 2.0 3.1 3.6 4.7 4.7 3.8
atorvastatin 2.4 2.2 2.1 2.2 1.7 2.1
rosuvastatin 0.8 0.9 0.9 1.2 1.2 1.0
pravastatin 0.4 0.7 0.8 1.3 1.4 1.0
lovastatin 0.7 0.8 0.5 0.5 0.4 0.5
fluvastatin 0.1 0.0 0.1 0.1 0.1 0.1
ezetimibe 2.7 3.0 2.2 1.6 1.2 2.0
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2006 2007 2008 2009 2010 Weighted Average
fenofibrate 1.4 1.2 1.2 1.3 1.2 1.3
gemfibrozil 0.5 0.6 0.6 0.5 0.6 0.5
Niacin 0.5 0.6 0.8 0.7 0.8 0.7
colesevelam 0.6 0.6 0.6 0.7 0.8 0.7
Diabetes
insulin (any type) 7.3 7.1 7.2 7.7 7.8 7.4
metformin 5.6 6.2 6.6 7.2 7.5 6.7
glipizide 2.2 2.2 2.1 2.2 2.0 2.1
glyburide 1.7 1.8 1.7 1.7 1.4 1.6
pioglitazone 1.1 1.8 1.6 1.6 1.4 1.5
glimepiride 1.4 1.3 1.4 1.4 1.4 1.4
sitagliptin 0.0 0.8 1.2 1.5 1.6 1.1
rosiglitazone 1.1 1.0 0.4 0.3 0.3 0.5
INFECTIOUS DISEASE
Antibacterials
amoxicillin 20.8 20.2 19.4 20.0 21.0 20.2
azithromycin 14.1 15.4 16.0 16.8 17.4 16.2
ciprofloxacin (systemic) 9.2 10.3 10.4 11.3 12.2 10.8
levofloxacin 11.2 11.2 9.9 8.9 7.9 9.6
trimethoprim/sulfamethoxazole 8.0 8.8 8.7 9.8 10.3 9.2
cephalexin 10.1 9.9 8.4 8.8 9.2 9.1
doxycycline 4.5 4.9 5.1 5.4 5.6 5.2
clindamycin (systemic) 5.0 5.1 4.9 5.4 5.3 5.2
moxifloxacin 3.5 3.8 3.6 3.2 2.9 3.4
penicillin v potassium 3.8 3.4 3.1 3.0 2.8 3.2
clarithromycin 3.8 3.3 3.2 2.8 2.8 3.1
rifaximin 1.1 1.5 1.6 2.0 3.0 1.9
erythromycin (systemic) 1.5 1.4 1.3 1.2 1.2 1.3
neomycin sulfate (systemic) 1.0 1.0 0.8 0.7 0.7 0.8
tetracycline 0.7 0.7 0.6 0.5 0.6 0.6
gentamicin 0.5 0.5 0.5 0.7 0.6 0.6
ofloxacin 0.5 0.7 0.5 0.4 0.4 0.5
rifampin 0.3 0.4 0.3 0.3 0.4 0.3
Antifungals
metronidazole 4.8 5.2 5.1 5.2 5.5 5.2
fluconazole 3.8 4.0 3.7 4.0 4.2 3.9
nystatin 2.6 2.8 2.5 2.7 3.0 2.7
ketoconazole 1.5 1.7 1.5 1.7 1.6 1.6
terbinafine 0.4 0.4 0.4 0.4 0.3 0.4
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2006 2007 2008 2009 2010 Weighted Average
itraconazole 0.0 0.1 0.1 0.1 0.1 0.1
voriconazole 0.0 0.0 0.0 0.1 0.1 0.1
posaconazole 0.0 0.0 0.0 0.0 0.0 0.0
Antivirals
valacyclovir 3.0 3.1 3.2 3.2 3.3 3.2
acyclovir 2.9 2.8 2.8 3.0 3.0 2.9
HIV
tenofovir 0.7 1.0 1.5 1.9 2.2 1.6
emtricitabine 0.5 0.9 1.3 1.6 1.8 1.3
ritonavir 0.5 0.8 1.0 1.2 1.1 1.0
lamivudine 1.0 0.8 0.9 1.0 0.9 0.9
efavirenz 0.6 0.5 0.8 0.9 1.0 0.8
atazanavir 0.2 0.4 0.4 0.6 0.6 0.5
abacavir 0.3 0.4 0.4 0.5 0.5 0.4
zidovudine 0.5 0.3 0.4 0.4 0.3 0.4
lopinavir/ritonavir 0.2 0.4 0.4 0.4 0.3 0.4
raltegravir N/A 0.0 0.1 0.3 0.4 0.2
darunavir 0.0 0.1 0.1 0.2 0.2 0.1
fosamprenavir 0.1 0.1 0.2 0.2 0.1 0.1
nevirapine 0.1 0.1 0.1 0.1 0.2 0.1
nelfinavir 0.1 0.1 0.1 0.1 0.1 0.1
didanosine 0.1 0.1 0.1 0.1 0.1 0.1
stavudine 0.1 0.1 0.1 0.1 0.1 0.1
etravirine 0.0 0.0 0.1 0.1 0.1 0.1
saquinavir 0.1 0.1 0.1 0.0 0.0 0.1
maraviroc 0.0 0.0 0.0 0.0 0.0 0.0
indinavir 0.0 0.0 0.0 0.0 0.0 0.0
delavirdine 0.0 0.0 0.0 0.0 0.0 0.0
tipranavir 0.0 0.0 0.0 0.0 0.0 0.0
MEN & WOMEN'S HEALTH
Hormone therapy
estradiol (excluding EE) 3.6 3.4 2.9 3.2 3.4 2.9
conjugated estrogens 3.1 2.8 2.3 2.3 2.0 2.4
testosterone 1.3 1.5 1.6 1.7 2.0 1.7
ethinyl estradiol (EE) 1.8 1.7 1.5 1.5 1.3 1.5
medroxyprogresterone 1.0 1.0 1.1 1.0 1.1 1.0
norethindrone 0.8 1.0 0.8 0.9 0.9 0.9
progesterone 0.5 0.6 0.6 0.7 0.7 0.6
drospirenone 0.3 0.3 0.3 0.3 0.2 0.3
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2006 2007 2008 2009 2010 Weighted Average
Erectile dysfunction
sildenafil (Viagra) 4.1 3.3 4.1 4.3 3.7 3.9
tadalafil (Cialis) 1.7 1.8 2.4 2.5 2.4 2.2
vardenafil 1.3 1.4 1.4 1.6 1.4 1.5
Benign prostatic hyperplasia
tamsulosin 1.8 2.3 2.5 3.0 3.0 2.6
doxazosin 0.6 0.6 0.7 0.7 0.7 0.7
terazosin 0.5 0.6 0.5 0.7 0.8 0.6
alfuzosin 0.2 0.3 0.4 0.3 0.3 0.3
GASTROINTESTINAL
Reflux
omeprazole 5.2 7.2 8.3 10.8 12.4 9.2
esomeprazole 8.4 8.4 7.1 7.1 6.1 7.2
pantoprazole 6.1 5.3 5.4 6.2 5.3 5.6
lansoprazole 5.8 5.0 4.1 3.7 3.8 4.3
ranitidine 1.7 1.7 1.5 1.7 1.7 1.7
rabeprazole 2.1 1.6 1.6 1.4 0.9 1.5
famotidine 1.0 1.2 0.9 1.3 1.2 1.1
cimetidine 0.2 0.2 0.2 0.1 0.2 0.2
Other
promethazine 10.6 10.8 9.8 10.3 9.7 10.1
lactulose 4.6 5.1 5.0 5.7 6.3 5.4
ondansetron 1.5 1.9 2.6 3.6 4.5 3.0
metoclopramide 3.0 3.4 3.0 2.9 2.0 2.8
ursodiol 2.0 1.8 1.8 2.1 2.2 2.0
mesalamine 0.6 0.6 0.5 0.6 0.6 0.6
domperidone 0.0 0.0 0.0 0.0 0.0 0.0
cisapride 0.0 0.0 0.0 0.0 0.0 0.0
OTHER
Asthma / Pulmonary disease
albuterol 8.8 8.8 8.7 9.9 10.2 9.4
fluticasone (in any product) 8.0 8.1 7.9 9.3 10.2 8.8
fluticasone (not in combination) 5.2 5.4 5.5 6.7 7.8 6.2
mometasone 3.8 3.7 3.5 3.2 3.2 3.4
salmeterol 3.5 3.3 3.0 3.2 3.0 3.2
fluticasone proprionate/salmeterol 3.4 3.2 2.9 3.2 2.9 3.1
montelukast 2.1 2.1 1.9 1.9 1.8 1.9
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2006 2007 2008 2009 2010 Weighted Average
ipratropium 1.9 1.9 1.8 2.0 1.8 1.9
tiotropium 1.1 1.3 1.2 1.3 1.4 1.3
budesonide 1.1 1.1 1.1 1.2 1.4 1.2
Arthritis / Osteoporosis
meloxicam 1.7 2.2 2.8 3.2 3.8 2.9
celecoxib 2.5 2.4 2.1 2.1 1.7 2.1
alendronate 1.9 1.7 1.8 1.8 1.7 1.8
hydroxychloroquine sulfate 0.8 0.8 0.8 0.9 1.0 0.9
risedronate 1.0 0.8 0.8 0.7 0.5 0.8
etanercept 0.4 0.4 0.4 0.5 0.5 0.4
Gout
allopurinol 1.3 1.2 1.3 1.6 1.6 1.5
colchicine 0.9 0.9 0.8 1.0 1.1 1.0
Steroids
prednisone 8.5 8.7 8.8 9.7 10.0 9.2
methylprednisolone 6.3 6.0 6.3 7.0 7.1 6.6
dexamethasone (systemic) 2.1 2.1 2.0 2.2 2.3 2.2
prednisolone 0.1 0.1 0.1 0.1 0.1 0.1
Other
levothyroxine 8.5 8.2 8.0 9.2 9.3 8.7
potassium chloride 5.4 5.2 5.3 5.6 5.5 5.4
benzonatate 2.5 2.4 2.7 3.0 2.9 2.7
diclofenac 2.0 1.9 2.5 3.0 3.5 2.7
warfarin 1.6 1.8 1.7 1.8 2.1 1.8
atropine 1.9 1.8 1.6 1.8 1.6 1.7
tamoxifen 0.1 0.2 0.1 0.1 0.1 0.1
ergonovine 0.0 0.0 0.0 0.0 0.0 0.0
References
1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of
hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006; 144(10):
705–14. [PubMed: 16702586]
2. Muhlberger N, Schawarzer R, Lettmeier B, Sroczynsk G, Zeuzem S, Siebert U. HCV-related burden
of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality.
BMC Public Health. 2009; 9:34. [PubMed: 19161623]
3. European Assocation for the Study of the Liver. EASL Clinical Practice Guidelines: management of
hepatitis C virus infection. J Hepatol. 2014; 60(2):392–420. [PubMed: 24331294]
4. Barritt AS, Fried MW. Maximizing opportunities and avoiding mistakes in triple therapy for
hepatitis C virus. Gastroenterology. 2012; 142(6):1314–1323. [PubMed: 22537438]
Lauffenburger et al. Page 43






















5. Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with
boceprevir and telaprevir. Hepatology. 2012; 55(5):1620–8. [PubMed: 22331658]
6. Weiss J, Becker JP, Haefeli WE. Telaprevir is a substrate and moderate inhibitor of P-glycoprotein,
a strong inductor of ABCG2, but not an activator of PXR in vitro. Int J Antimicrob Agents. 2014;
43(2):184–8. [PubMed: 24332840]
7. Hulskotte EG, Feng HP, Xuan F, van Zutven MG, Treitel MA, Hughes EA, et al. Pharmacokinetic
interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1
protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis. 2013; 56(5):718–26.
[PubMed: 23155151]
8. Garg V, Chandorkar G, Yang Y, Adda N, McNair L, Alves K, et al. The effect of CYP3A inhibitors
and inducers on the pharmacokinetics of telaprevir in healthy volunteers. Br J Clin Pharmacol.
2013; 75(2):431–9. [PubMed: 22642697]
9. Hammond KP, Wolfe P, Burton JR Jr, Predhomme JA, Ellis CM, Ray ML, et al. Pharmacokinetic
interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acquir
Immune Defic Syndr. 2013; 62(1):67–73. [PubMed: 23075915]
10. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al. Efficacy of boceprevir, an
NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive
patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre
phase 2 trial. Lancet. 2010; 376(9742):705–16. [PubMed: 20692693]
11. Bifano M, Hwang C, Oosterhuis B, Hartstra J, Grasela D, Tiessen R, et al. Assessment of
pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with
antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther. 2013;
18(7):931–40. [PubMed: 23963204]
12. Burger D, Back D, Buggisch P, Buti M, Craxi A, Foster G, et al. Clinical management of drug-
drug interactions in HCV therapy: challenges and solutions. J Hepatol. 2013; 58(4):792–800.
[PubMed: 23137766]
13. van Heeswijk RP, Beumont M, Kauffman RS, Garg V. Review of drug interactions with telaprevir
and antiretrovirals. Antivir Ther. 2013; 18(4):553–60. [PubMed: 23344266]
14. Wilby KJ, Greanya ED, Ford JA, Yoshida EA, Partovi N. A review of drug interactions with
boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol. 2012; 11(2):
179–85. [PubMed: 22345334]
15. Back D, Else L. The importance of drug-drug interactions in the DAA era. Dig Liver Dis. 2013;
45(Suppl 5):S343–8. [PubMed: 24091114]
16. Maasoumy B, Port K, Calle Serrano B, Markova AA, Sollik L, Manns MP, et al. The clinical
significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic
hepatitis C. Aliment Pharmacol Ther. 2013; 38:1365–72. [PubMed: 24127648]
17. Louie KS, St Laurent S, Forssen UM, Mundy LM, Pimenta JM. The high comorbidity burden of
the hepatitis C virus infected population in the United States. BMC Infect Dis. 2012; 12:86.
[PubMed: 22494445]
18. El-Zayadi AR. Hepatitis C comorbidities affecting the course and response to therapy. World J
Gastroenterol. 2009; 15(40):4993–9. [PubMed: 19859990]
19. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the
Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using
data from 6 countries. Am J Epidemiol. 2011; 173(6):676–82. [PubMed: 21330339]
20. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J
Clin Epidemiol. 1994; 47(11):1245–51. [PubMed: 7722560]
21. University of Liverpool HIV & Hepatitis Pharmacology Group Drug Interaction Charts. [Online,
09 April 2014] Available from: http://www.hep-druginteractions.org/Interactions.aspx
22. Merck & Co., Inc. Highlights of prescribing information: Victrelis. Whitehouse Station, NJ: 2011.
[Online, 09 April 2014] Available from: http://www.merck.com/product/usa/pi_circulars/v/
victrelis/victrelis_pi.pdf
23. Vertex Pharmaceuticals. Highlights of prescribing information: Incivek. Cambridge, MA: 2011.
[Online,09 April 2014]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/
2011/201917lbl.pdf
Lauffenburger et al. Page 44






















24. Poordad F, McCone J Jr, Macon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for
untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364(13):1195–206. [PubMed:
21449783]
25. Bacon BR, Gorden SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for
previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364(13):1207–17.
[PubMed: 21449784]
26. Poordad, F.; Lawitz, E.; Gordon, S.; Bouliere, M.; Vierling, JM.; Poynard, T., et al. American
Society of Liver Diseases. San Francisco: 2011. Concomitant Medication use (drug interactions) in
Patients with Hepatitis C Genotype 1 Treated with Boceprevir Combination Therapy.
27. Basseri B, Yamini D, Chee G, Enayati PD, Tran T, Poordad F. Comorbidities associated with the
increasing burden of hepatitis C infection. Liver Int. 2010; 30(7):1012–8. [PubMed: 20408945]
28. Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected
in clinical trials. Cleve Clin J Med. 2011; 78(6):393–403. [PubMed: 21632911]
29. Anglicheau D, Flamant M, Schlageter MH, Martinez F, Cassinat B, Beaune P, et al.
Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation.
Nephrol Dial Transplant. 2003; 18(11):2409–14. [PubMed: 14551375]
30. Konishi H, Sumi M, Shibata N, Takada K, Minouchi T, Yamaji A. Influence of intravenous
methylprednisolone pulse treatment on the disposition of ciclosporin and hepatic CYP3A activity
in rats. J Pharm Pharmacol. 2004; 56(4):477–83. [PubMed: 15099443]
31. Leutscher PD, Lagging M, Buhi MR, Pederson C, Norkrans G, Langeland N, et al. Evaluation of
depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology. 2010; 52(2):
430–5. [PubMed: 20683942]
32. Sockalingam S, Tseng A, Giguere P, Wong D. Psychiatric treatment considerations with direct
acting antivirals in hepatitis C. BMC Gastroenterol. 2013; 13:86. [PubMed: 23672254]
33. Smith HS. Opioid metabolism. Mayo Clin Proc. 2009; 84:613–24. [PubMed: 19567715]
34. Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacological
interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications
and management for clinical practice. Expert Rev Clin Pharmacol. 2013; 6:249–69. [PubMed:
23656339]
35. Guggenheimer J, Moore PA. The therapeutic applications of and risks associated with
acetaminophen use: a review and update. J Am Dent Assoc. 2011; 142:38–44. [PubMed:
21193765]
36. Kunze A, Huwyler J, Camenisch G, Gutmann H. Interaction of the antiviral drug telaprevir with
renal and hepatic drug transporters. Biochem Pharmacol. 2012; 84:1096–102. [PubMed:
22902721]
37. Chu X, Cai X, Cui D, Tang C, Ghosal A, Chan G, et al. In vitro assessment of drug-drug
interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
Drug Metab Dispos. 2013; 41:668–81. [PubMed: 23293300]
38. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Interaction
between polymorphisms in the OCT1 and MATE1 transporter and metformin response.
Pharmacogenet Genomics. 2010; 20:38–44. [PubMed: 19898263]
39. Lau YY, Huang Y, Frassetto L, Benet LZ. Effect of OATP1B transporter inhibition on the
pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2007; 81:194–204.
[PubMed: 17192770]
40. Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y. Involvement of transporters
in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II
AT1-receptor, in humans. Drug Metab Dispos. 2006; 34:1247–54. [PubMed: 16624871]
41. Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H, et al.
Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res. 2005;
11:2320–6. [PubMed: 15788683]
42. Allred AJ, Bowen CJ, Park JW, Peng B, Williams DD, Wire MB, et al. Eltrombopag increases
plasma rosuvastatin exposure in healthy volunteers. Br J Clin Pharmacol. 2011; 72:321–9.
[PubMed: 21434975]
Lauffenburger et al. Page 45






















43. Volk EL, Schneider E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a
methotrexate polyglutamate transporter. Cancer Res. 2003; 63:5538–43. [PubMed: 14500392]
44. Huang L, Wang Y, Grimm S. ATP-dependent transport of rosuvastatin in membrane vesicles
expressing breast cancer resistance protein. Drug Metab Dispos. 2006; 34:738–42. [PubMed:
16415124]
45. Polli JW, Humphreys JE, Harmon KA, Castellino S, O'Mara MJ, Olson KL, et al. The role of
efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-
(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib)
disposition and drug interactions. Drug Metab Dispos. 2008; 36:695–701. [PubMed: 18216274]
46. Yeo KR, Jamei M, Rostami-Hodjegan A. Predicting drug-drug interactions: application of
physiologically based pharmacokinetic models under a systems biology approach. Expert Rev Clin
Pharmacol. 2013; 6:143–57. [PubMed: 23473592]
47. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A. The Simcyp
population-based ADME simulator. Expert Opin Drug Metab Toxicol. 2009; 5:211–23. [PubMed:
19199378]
48. Caccia S, Garattini S, Pasina L, Nobili A. Predicting the clinical relevance of drug interactions
from pre-approval studies. Drug Saf. 2009; 32:1017–39. [PubMed: 19810775]
49. Perkins NA, Murphy JE, Malone DC, Armstrong EP. Performance of drug-drug interaction
software for personal digital assistants. Ann Pharmacother. 2006; 40:850–5. [PubMed: 16622155]
50. Stepanova M, Kanwal F, El-Serag HB, Younossi ZM. Insurance status and treatment candidacy of
hepatitis C patients: analysis of population-based data from the United States. Hepatology. 2011;
53:737–45. [PubMed: 21319199]
51. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and
ribavirin in treatment-naive genotype 1 hepatitis C: The randomized PILLAR study. Hepatology.
2013; 58:1918–29. [PubMed: 23907700]
52. Rodriguez-Torres M, Lawitz E, Kowdley KV, et al. Sofosbuvir (GS-7977) plus peginterferon/
ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging
trial. J Hepatol. 2013; 58:663–8. [PubMed: 23183528]
53. Li Y, Zhou J, Ramsden D, Taub ME, O'Brien D, Xu J, Busacca CA, et al. Enzyme-transporter
interplay in the formation and clearance of abundant metabolites of faldaprevir found in excreta
but not in circulation. Drug Metab Dispos. 2014; 42(3):384–93. [PubMed: 24346834]
54. Bertz R. 14thInternational Workshop on Clincial Pharmacology of HIV Therapy. 2013 Session 5.
55. Sabo J, Kort J, Haschke M, Ballow C, Girlich B, Feifel U, et al. Pharmacokinetic interactions of
darunavir/ritonavir, efavirenz, and tenofovir with the hepatitis C virus protease inhibitor
faldaprevir in healthy volunteers. 20th CROI. 2013 Oral abstract 35.
56. Kiser JJ, Flexner C. Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev
Pharmacol Toxicol. 2013; 53:427–49. [PubMed: 23140245]
Lauffenburger et al. Page 46







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Eur J Gastroenterol Hepatol. Author manuscript; available in PMC 2015 October 01.
